# Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic Carcinosarcoma

> **NCT04149275** · PHASE2 · WITHDRAWN · sponsor: **University of Alabama at Birmingham**

## Conditions studied

- Carcinosarcoma of Ovary
- Carcinosarcoma of Uterus
- Carcinosarcoma of Vagina

## Interventions

- **DRUG:** Cabozantinib
- **DRUG:** Ipilimumab
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT04149275
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-02
- **Primary completion:** 2021-02
- **Final completion:** 2021-02
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Funding withdrawn by sponsor
- **Last updated:** 2021-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04149275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04149275, "Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic Carcinosarcoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04149275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*